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Abstract: Cetuximab is a monoclonal antibody able to inhibit and to degrade the transmembrane 
receptor Her-1, also known as epidermal growth factor receptor (EGFR). The inhibition of EGFR 
is of major importance since the receptor inﬂ  uences many important tumor cell activities includ-
ing tumor growth, neo-angiogenesis, inhibition of the apoptotic response to chemotherapy and 
radiotherapy. Available experimental data suggest that cetuximab may enhance chemotherapy 
and radiotherapy activity, reverse resistance to some anticancer drugs and has itself anticancer 
activity. Early clinical data support experimental results. This paper reviews the published 
experiences on cetuximab in the treatment of advanced head and neck cancer and points out 
the future objectives of the clinical research on this drug.
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Background
Cetuximab recently received both the FDA and EMEA approval for the treatment 
of patients with locally advanced squamous cell carcinoma of the head and neck 
(SCCHN). Cetuximab is a chimeric human- murin immunoglobulin G1 (IgG1) mono-
clonal antibody that binds the epidermal growth factor receptor (EGFR) with high 
speciﬁ  city and competitively inhibits endogenous ligand binding (Sato et al 1983; 
Gill et al 1984; Goldstein et al 1995). The link between cetuximab and EGFR induces 
receptor dimerization, internalization and degradation (Fan et al 1994; Schlessinger 
2000; Herbst and Shin 2002).
EGFR is a 170-kd transmembrane glycoprotein, member of the ErbB family of 
tyrosine kinase receptors, composed by an extra cellular ligand-binding domain, a 
trasmembrane lipophilic segment and an intracellular protein kinase domain with a 
regulatory carboxyl terminal segment. After binding with its ligands, EGFR occurs 
dimerization, posphorylation of the tyrosin kinase, activating the receptor pathway, 
internalization and degradation (Thomson and Gill 1985; Schlessinger 1988; Carpenter 
and Cohen 1990; Ulrich and Schlessinger 1990; Olayioye et al 2000; Schleissinger 2000; 
Yarden and Sliwkowski 2001; Mendelsohn and Baselga 2003; Hynes and Lane 2005).
In SCCHN the EGFR overexpression is associated with more aggressive disease, 
increased resistance to chemotherapy and radiotherapy, increased metastasis, inhibi-
tion of apoptosis, promotion of neoplastic angiogenesis, and, ﬁ  nally, poor prognosis 
and decreased survival (Santini et al 1991; Grandis et al 1998; Nicholson et al 2001; 
Ang et al 2002, 2004; Gupta et al 2002; O-Charoenrat et al 2002; Eriksen et al 2004). 
However, experimental studies demonstrated that the blockade of EGFR by mono-
clonal antibodies (Mabs) or by tyrosin- kinase inhibitors reverts radio resistance and 
enhances radiosensivity and chemosensivity in human SCCHN cell lines in vitro and 
in vivo (Goldstein et al 1995) .
In clinical practice, EGFR expression is evaluated using a standardized immu-
noistochemistry (IHC) assay, designated to asses cell membrane staining. EGFR Therapeutics and Clinical Risk Management 2007:3(5) 872
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expression is reported by the maximal intensity of the IHC 
stain in the cytoplasm on an ordinal scale of 0 to 3 (Goldstein 
et al 1995; O-Charoenrat et al 2002). Unfortunately IHC 
is a semi-quantitative methodology allowing wide inter-
lab-differences. Moreover it has not yet been shown any 
quantitative relationship between EGFR expression and 
clinical response to its inhibition, so that the role of EGFR 
expression to predict response to EGFR targeting agents is 
unclear.
Cetuximab and radiotherapy
Robert et al (2001) evaluated a combination of escalating 
doses of cetuximab concurrent with radiotherapy in a phase 
I study. The momoclonal antibody was given from 100 to 
500 mg/m2 loading dose and from 100 to 250 mg/m2 weekly 
maintenance dose to patients with SCCHN. Cetuximab 
did not worse the usual radiation therapy side effects and 
added only mild to moderate skin reaction. Unfortunately 
one patient was removed from the study, due to grade IV 
anaphylactic reaction. Objective responses were achieved 
in all the patients and they were complete in most cases. In 
conclusion Robert at al showed that cetuximab can be added 
to RT at the standard clinical dose (400 mg/m2 loading dose 
and 250/m2 weekly maintenance doses) without any dose 
limiting toxicity.
On these bases Bonner et al (2006) conducted and 
published a phase III trial. In this study 424 patients with 
locoregional advanced head and neck cancer were randomly 
assigned to radiotherapy alone or the same radiotherapy plus 
weekly cetuximab at the standard clinical dose. The accrued 
patients had stage III or IV not previously treated, histologi-
cally proven, squamous cell carcinoma arising from orophar-
inx, hypopharinx and larynx. Overall 13 pts discontinued 
cetuximab, mostly because of hypersensitivity reactions 
(4 pts) or acneiform rush (8 pts). With the exception of these 
toxicities, the incidence of severe reactions was similar in the 
two treatment arms conﬁ  rming that cetuximab does not exac-
erbate the common radiotherapy related side effects (Table 1). 
The experimental arm signiﬁ  cantly improved loco-regional 
control and median survival: 24.4 months vs 14.9 (p = 0.005) 
and 49 vs 29.3 months (p = 0.03) respectively, compared 
to radiotherapy alone. Thus the Bonner’s trial shows that 
cetuximab plus radiotherapy is superior to radiotherapy alone. 
Interestingly, this is the ﬁ  rst trial showing that the results of 
radiotherapy can be signiﬁ  cantly improved by the addition 
of a drug without worsening radiotherapy toxicity.
The weakness of the Bonner’s trial is its control arm, since 
radiotherapy alone is no longer the standard treatment of most 
SCCHN patients. Indeed a number of meta-analyses have 
shown that chemo-radiation is a more appropriate standard 
treatment in advanced unresectable SCCHN (Merlano and 
Marchetti 2003).
However radiotherapy remains a good option when 
adequate clinical expertise is not available or in any other 
Table 1 Comparison of major toxicities according to treatment plan (% of patients)
  Column A  Column B  Column C  Column D  Column E  Statistical signiﬁ  cance
 RT  RT  cisplatin  RT  alonea cisplatin  +
 cetuximaba cisplatin  cetuximabc   placeboc
   cetuximabb
Mucositis   56  24  0  52  0  ns
Acneiform rash  17  23  16  1  0  Column A vs D
            p < 0.001
            Column C vs E
            p < 0.001
Dehydration 6  33  12  8  10  ns
Anemia 1 9.5  15  6 9  Column  A  vs  D
            p = 0.006
Allergic reaction  3  4.8  6  0  2  Column A vs D
            p = 0.01
Infection 1  9.5  15  1  10  ns
Hypomagnesemia  NS  NS  13  NS  0  Column C vs E
            p = 0.006
Most common grade 3–5 adverse events that occurred or reached a difference statistically signiﬁ  cant.
RT, radiotherapy; NS, not stated; ns, not signiﬁ  cant.
aFrom Bonner et al (2006).
bFrom Pﬁ  ster et al (2006).
cFrom Burtness et al (2005).Therapeutics and Clinical Risk Management 2007:3(5) 873
Cetuximab in head and neck cancer
situation precluding chemotherapy. The Bonner trial suggests 
that in these conditions radiotherapy and cetuximab should 
be regarded as the new standard. On the contrary it is unclear 
whether cetuximab may be as effective as chemotherapy 
combined with radiotherapy, due to the lack of comparative 
trials.
Cetuximab and chemotherapy
It has been suggested that palliative chemotherapy may 
achieve advantage in quality of life and a survival over best 
supportive care (Stell et al 1983; Constenla et al 1997; Leon 
et al 2004). However all the patients with recurrent disease 
not suitable for savage surgery and/or radiotherapy, will die 
of their disease, eventually.
Due to the poor outcome of these patients there is a need 
for new active agents. Cetuximab may theoretically play an 
important role in this setting of patients: the different mecha-
nism of action compared to conventional chemotherapeutic 
drugs should favor the lack of cross resistance and the poor-
ness of side effects should allow the treatment of patients 
with low performance status.
Trigo et al (2004) evaluated cetuximab alone in 103 
patients refractory to cisplatin based chemotherapy. The most 
frequent adverse event was skin rash/acne reaction which 
happened in 80% of patients (1% grade 3). There was one 
treatment related death due to hypersensitivity reaction.
Seventeen patients achieved an objective response includ-
ing 5 complete responses (Objective Response Rate 16.5%) 
and the median survival of the whole patients population was 
5.9 months. Both the response rate and the median survival 
are similar to that expected with platinum alone in chemo-
therapy naive patients (Forastiere et al 1992). The observed 
activity and the limited toxicity prompt the Researchers to 
test cetuximab in combination with chemotherapy.
Baselga et al (2000) was the ﬁ  rst to report phase I clinical 
trials testing the feasibility of combining cisplatin and cetux-
imab. The study end points were to establish safety proﬁ  le, to 
determine the optimum biologic dose, the maximum tolerated 
dose and the pharmacologic proﬁ  le of cetuximab alone or in 
combination with cisplatin. Fifty-two patients were treated 
in three successive phase I clinical trials in which cetuximab 
was given as a single dose (13 pts), weekly multiple dose 
(17 pts) and weekly multiple dose with cisplatin (22 pts). 
These trials demonstrated the safety of cetuximab given alone 
or in combination with chemotherapy.
Bourhis in a further trial evaluated the combination of 
cetuximab with cisplatin, or carboplatin, and ﬂ  uorouracil. 
The treatment was tolerable allowing full dose of the 
cytotoxic agents, due to the absence of overlapping toxicities 
(Bourhis et al 2006).
Therefore, cetuximab can be safely added to chemotherapy, 
and, considering the different toxic proﬁ  le and its demon-
strated activity, could improve chemotherapy results. On 
these bases Burtness et al (2005) conducted a double-blind 
randomized phase III trial comparing cisplatin and cetuximab 
(arm A) with cisplatin and Placebo (arm B). The combination 
arm experienced signiﬁ  cantly more frequent neutropenia, 
hypomagnesemia and skin toxicity. Skin toxicity in particu-
lar was 77% in arm A (grade 3 in 23%) and 24% in arm B 
(no grade 3). Surprisingly hypersensitivity were expressed in 
both arms, 3% of grade 3 and 3% of grade 4 in arm A, 2% of 
grade 3 and 0% grade 4 in arm B (Table 1). The combination 
of cetuximab and cisplatin gave a signiﬁ  cant higher response 
rate than placebo and cisplatin (36% vs 10%, p 0.03). The 
response rate for the patients in arm A who developed skin 
toxicity was 33% compared to 7% in patients who did not. 
This difference is not statistically signiﬁ  cant (p = 0.08). 
However skin toxicity was associated with a statistically 
signiﬁ  cant survival improvement (p = 0.01). The progression 
free survival (PFS) and the overall survival (OS) showed a 
trend in favor of arm A, but did not meet the statistical sig-
niﬁ  cance. This study demonstrated that cetuximab increases 
the antitumor activity of cytotoxic chemotherapy and that 
survival is improved in patients developing skin reaction. 
Even Salz et al (2003), described the relationship between 
skin rush and prolonged survival in an earlier report.
An additional way to employ cetuximab and chemotherapy 
arises from the relationship between EGFR overexpression 
and drug resistance. EGFR phosphorilation results in the 
activation of multiple pathways including PI3K- AKT. 
This way enhances BCL-2 activity, inhibiting the apoptotic 
response to chemotherapy and radiotherapy. Thus the inhibi-
tion of EGFR should downregulate BCL-2 activity, restoring 
apoptotic response to chemotherapy and radiotherapy (Huang 
et al 1999; Huang and Harari 2000; Harari and Huang 2001). 
This is why cetuximab has been combined with some chemo-
therapeutic drugs, to treat patients with already demonstrated 
refractory disease to the same drugs.
Herbst and Baselga respectively conducted and pub-
lished two phase II trials in platinum refractory patients with 
SCCHN. Herbst et al (2005) treated with cetuximab and 
cisplatin patients not responders to, or progressed during, 
cisplatin/paclitaxel or cisplatin/ﬂ  uorouracil. Patients accrued 
were grouped in 3 groups according to response to prior 
regimen: group 1 = stable disease, group 2 = on treatment 
progressive disease, group 3 = progression within 90 days Therapeutics and Clinical Risk Management 2007:3(5) 874
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from the end of therapy. Patients received cetuximab at the 
conventional clinical dose and cisplatin 75 or 100 mg/m2 
every 3 weeks. Cetuximab did not show any effects on phar-
macokinetic proﬁ  le of cisplatin and cisplatin-based toxicity 
was not exacerbated by cetuximab. The objective response 
rates were 18%, 20%, and 6% in the three groups respec-
tively. The PFS and the OS were greater in group 1 (4.2 and 
11.7 months) compared to group 2 (3 and 6.1 months) and 
group 3 (2 and 4.3 months).
Baselga et al (2005) treated 96 patients platimum refrac-
tory, with cetuximab and cisplatin or carboplatin according 
to an every 3 weeks scheduling or an every 4 weeks. The 
response rate was 10% with 53% of disease control rate. The 
median time to progression (TTP) and the overall survival 
(OS) were 85 and 183 days. There was a trend in favor of 
partial responders in terms of TTP and OS, and, similarly in 
patients treated with the every 3 weeks schedule compared 
to every 4 weeks. The skin reaction and acne – like rash were 
the most common adverse events, 80% and 72% respectively. 
They were grade 3 in 2% and grade 4 in 1%. The patients who 
developed a grade 1 or 2 skin reaction achieved a prolonged 
TTP and OS.
These studies can be interpreted in two ways: The ﬁ  rst is 
that cetuximab can reverse cisplatin resistance in a small but 
signiﬁ  cant number of patients without any major additional 
toxicity; the second is that cetuximab could be the only drug 
achieving interesting response rate in second line treatment of 
advanced SCCHN. Data on activity of cetuximab in advanced 
head and neck cancer are summarized in Table 2.
Cetuximab and chemoradiation
As stated above, chemo-radiation is the standard of care for 
most patients with SCCHN. Data on cetuximab combined 
with chemo-radiation are lacking. At present there are two 
main unanswered questions on this matter. The ﬁ  rst is wheth-
er cetuximab combined with radiotherapy may be at least as 
effective as chemo-radiation. We have no way to answer this 
question, unless a comparative randomized trial is performed. 
In our knowledge, there are no such published trials.
The second question is whether cetuximab may add to 
chemo-radiation in terms of major end-points: survival, 
disease free survival and complete responses. This second 
question is more complex and requires multi-level evalua-
tion. The ﬁ  rst level is to understand whether cetuximab can 
be safely added to chemo-radiation. The second is to point 
out the appropriate dosage and scheduling. The third is to 
investigate whether the level of activity of such combination 
may be of interest for future phase III trials. The last step is 
to compare chemo-radiation to the same plus cetuximab in 
a randomized setting.
To day only Pﬁ  ster et al (2006) reported a trial of chemo-
radiation combined with cetuximab in a full paper. All the 
evaluable patients entering this study achieved an objective 
response, but two grade V events occurred, leading the Au-
thors to close the trial in advance. The investigators considered 
the relationship between the two on treatment deaths and the 
investigational regimen, uncertain. However, additional non 
fatal, but signiﬁ  cant adverse events occurred prompting study 
closure. The major toxicities encountered by Pﬁ  ster et al are 
listed in Table 1.
However, at 3 years median follow-up, PFS and OS 
were 59 e 76% respectively suggesting a favorable effect by 
the addition of cetuximab to chemoradiation. The authors 
concluded that the search for a less toxic regimen combined 
cetuxumab and chemo-radiation is highly recommended 
(Pﬁ  ster et al 2005).
The Authors’ group reported in abstract form an on-going 
experience of rapidly alternating chemoradiation and 
cetuximab (Merlano et al 2005). Alternating chemo-radiation 
is a minor variation of concurrent chemo-radiation aimed to 
reduce toxicity (Merlano 2006). This is why we are using this 
approach in a phase II trial of combined chemo-radiotherapy 
and cetuximab. At present, 31 patients have been accrued 
and 18 are fully evaluble. No major toxicity occurred and 
Table 2 First line palliative treatment of advanced SCCHN
 Responders  Non  NE  PFS  OS
   responders
Cetuximaba 16.5%  82.5%  1%  2.8  m  5.8  m
Cisplatin and Placebob  10%  90%    2.7 m  7.9 m
Cisplatin and Fluorouracilc 29.8%  59.6%  10.6  NS  8.7  m
Cisplatin and Paclitaxelc 26%  60%  14  NS  8.1  m
Ciplatin and Cetuximabb  26%  74%    4.2 m  9.2 m
NE, not evaluable; PFS, progression free survival; OS, overall survival; m, months; NS, not stated.
aTrigo et al (2004).
bBurtness et al (2005).
cGibson et al (2005).Therapeutics and Clinical Risk Management 2007:3(5) 875
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all the patients achieved an objective response, including 13 
complete responses. The study has a planned accrual of 45 
patients; therefore, the ﬁ  nal analysis is foreseen within 2007. 
Other phase II studies of chemo-radiation and cetuximab 
are in progress worldwide and results of some of these are 
expected soon. Notwithstanding the lack of deﬁ  nitive data 
from phase II studies, the RTOG has designed and activated 
a phase III trial of deﬁ  nitive chemo-radiation plus or minus 
cetuximab (Harari and Huang 2006). Data will be available 
in the forthcoming years.
Therefore we cannot understand yet the true role of the 
combination of cetuximab and chemo-radiation in SCCHN, 
due to the lack of deﬁ  nitive data; this treatment must be still 
regarded as an experimental approach not to use outside of 
clinical trials.
Conclusion
Cetuximab is the ﬁ  rst monoclonal antibody showing clinical 
activity in SCCHN. Available data support its use in patients 
refractory to platinum/ﬂ  uorouracil or platinim/paclitaxel. 
Preliminary data also suggests that cetuximab can be given 
in combination with cisplatin in chemotherapy naïve patients, 
with positive impact on response rate and overall survival. It 
is possible that, if cetuximab will be added to a more stan-
dard palliative chemotherapy, ie, cisplatin and paclitaxel or 
cisplatin and ﬂ  uorouracil, the beneﬁ  t could be more evident. 
Moreover, further investigations should take into account the 
end point “quality of life” systematically including the use 
of validate questionnaires.
More convincing data suggest the use of cetuximab in 
combination with radiotherapy, at least in patients not can-
didate for chemo-radiation. The results of the Bonner’s trial 
showed not only signiﬁ  cant improvements in all the major 
and-points, but also that radiotherapy toxicity remained 
unchanged notwithstanding the addition of cetuximab. We 
have not yet randomized phase III trials comparing chemo-
radiation and cetuximab-radiation, but considering that 
chemo-radiation is a highly toxic treatment, such trial is 
recommended.
Finally, the combination of cetuximab and chemo-
radiotherapy is a ﬁ  eld almost completely uninvestigated. 
The only published trial recorded two on treatment deaths, 
but their relationship with the addition of cetuximab is 
unclear. Other preliminary data from ongoing studies do not 
show any signiﬁ  cant worsening of toxicity at the moment. 
However, available data are inadequate to suggest the use 
of cetuximab during a chemo-radiotherapy program outside 
clinical trials.
In conclusion, cetuximab represents an important new 
drug in the management of SCCHN. Furthermore clinical 
investigations on cetuximab are still ongoing. Therefore 
additional advantage by the introduction of cetuximab in the 
daily clinical practice may be expected in the future.
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